This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Voss, M. H. et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.9084 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Papillary features predict survival in ncRCC. Nat Rev Clin Oncol 13, 652–653 (2016). https://doi.org/10.1038/nrclinonc.2016.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.159